Azaprin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azaprin

Property Description
Active Ingredient Azathioprina (Azathioprine)
Form Tablet, Injectable solution
Pharmacological Class Immunosuppressant, Antimetabolite
Common Use Immune system modulation, Transplant rejection prevention
Origin Synthetic compound

What Type of Medicine is Azaprin?

Azaprin is a potent, synthetic compound containing the active ingredient Azathioprina (azathioprine). It is primarily classified as an immunosuppressant and an antimetabolite, a pharmacological class that acts systemically throughout the body. The utility of this classification is widely clinically recognized for managing conditions where immune system overactivity is central to pathology.

This medication is designated as a systemic agent used for chronic treatment. Azathioprina functions as a purine analog, meaning it mimics natural chemical building blocks to interfere with cell processes. Azathioprine is a well-established agent in this category, often referred to by common brand names like Imuran. It is supplied as a single-ingredient product, typically in tablet form for oral administration, and also as an injectable solution for intravenous use, offering flexibility for managing treatment initiation.

Azathioprina: Composition and General Therapeutic Purpose

The core therapeutic effect of Azaprin is directly linked to its composition, which involves the prodrug Azathioprina being metabolized into the active compound 6-mercaptopurine. This active metabolite interferes with the body's natural purine synthesis pathway, which is essential for the rapid growth of immune cells like T-lymphocytes and B-cells.

The general therapeutic purpose of utilizing Azaprin is to provide sustained immunosuppressive therapy. By disrupting the multiplication and function of these cells, the medication helps control the inflammation that characterizes autoimmune diseases and is essential for preventing the rejection of transplant organs. This controlled immunomodulation aims to minimize long-term tissue damage and preserve the function of affected organs.

Regulatory References

  1. NIH/StatPearls

What side effects are possible with Azaprin?

Possible Side Effects and Safety Information for Azaprin

Azaprin (Azathioprine) is an immunosuppressive medication with a complex safety profile, primarily associated with dose-related toxicities and long-term risks due to its mechanism of action. Official regulatory documentation highlights the necessity of patient monitoring and specific risk mitigation strategies.

Key Adverse Reactions and Safety Concerns

The most significant and potentially life-threatening risks are associated with hematologic toxicity and an increased risk of malignancies.

  • Hematologic Toxicity: Azaprin can cause severe bone marrow suppression, leading to leukopenia (low white blood cells), thrombocytopenia (low platelets), and anemia. These effects are often dose-related and necessitate frequent monitoring of complete blood counts.
  • Malignancy Risk: Long-term immunosuppression increases the risk of developing certain cancers, including lymphomas (such as Hepatosplenic T-cell Lymphoma) and skin cancer.
  • Infections: As an immunosuppressant, Azaprin increases susceptibility to severe viral, bacterial, and fungal infections.

Population-Specific and Serious Considerations

Category Safety Consideration
Genetic Risk Patients with genetically low or absent Thiopurine S-Methyltransferase (TPMT) enzyme activity are at a significantly heightened risk of severe, life-threatening myelotoxicity. Regulatory guidance recommends pre-treatment testing.
Pregnancy Azaprin is generally considered contraindicated during pregnancy for certain conditions due to the risk of fetal harm (e.g., prematurity, low birth weight). Adequate contraception is required during and for a period after therapy.
Organ Dysfunction Caution and dose adjustment are required in patients with pre-existing renal or hepatic impairment (kidney or liver disease).
Gastrointestinal Pancreatitis is a serious adverse reaction, particularly noted in patients with Inflammatory Bowel Disease.

Summary of Adverse Reaction Frequency

Common side effects (affecting 1% to 10% of patients) include alopecia (hair loss). Anorexia is noted as a very common effect (affecting 10% or more). Hypersensitivity reactions, sometimes fatal, are classified as uncommon or rare. The overall safety structure mandates that Azaprin must be managed under close medical supervision with full recognition of its risks as an agent with both mutagenic potential and immunosuppressive effects.

Overdose and Emergency Response

Overdose and when to seek help

Feature Official Regulatory Statement
Documented overdose presentations Acute symptoms include severe nausea, severe vomiting, and diarrhea. The primary, delayed manifestation is bone marrow suppression (myelotoxicity), signaled by ulceration of the throat, fever, infections, or unexplained bleeding.
Physiological systems affected Primarily the Hematological system (severe leukopenia, pancytopenia) and the Gastrointestinal system. Monitoring of Hepatic function is also required.
Population-specific overdose notes Individuals with documented low or absent thiopurine S-methyl transferase (TPMT) enzyme activity face an increased risk of severe, life-threatening myelotoxicity.
Classification Aspect Official Regulatory Statement
Severity classification Overdose is classified as capable of causing severe and life-threatening myelotoxicity.
Antidote status No specific antidote is known for Azaprin.
Immediate required action Seek immediate medical attention for all suspected overdoses. Call emergency services if the person collapses, has a seizure, or has difficulty breathing.

Official Overdose Statements

  • The critical toxic consequence is the delayed onset of severe bone marrow suppression; the lowest blood count (nadir) typically occurs 9 to 19 days after overdose.
  • Management is strictly supportive and symptomatic. Procedural options noted in regulatory documents include the administration of activated charcoal (if given acutely) and dialysis, as the compound is dialyzable.
  • Blood count and liver enzyme monitoring are required for ongoing observation due to the risk of delayed hematologic toxicity.

Connection to the overall overdose profile

Regulatory documents define the overdose profile around the critical, delayed risk of myelotoxicity rather than just acute symptoms. This documented potential for severe, late-onset toxicity dictates the mandatory help-seeking conditions, requiring immediate medical evaluation for all suspected exposures and prolonged professional monitoring for hematological safety.

Therapeutic Uses of Azaprin

What Azaprin Treats: Main Uses and Benefits

The medication is used across therapeutic domains involving chronic, unchecked immune activity. Its use is relevant for managing conditions characterized by periods of heightened symptoms and systemic discomfort.

The medication is commonly used for managing conditions such as Rheumatoid Arthritis, severe forms of Lupus Nephritis, certain vasculitis disorders, and chronic Inflammatory Bowel Disease (including Crohn's disease and Ulcerative Colitis). It is commonly used as a necessary part of post-transplant regimens, primarily for kidney allografts, where it plays a role in managing conditions where functional stability becomes affected.

“This supportive use may contribute to maintaining functional stability during periods of heightened symptoms.”

In these contexts, Azaprin is applied in addressing the chronic, aggressive inflammation that drives symptoms related to physical discomfort and organ-specific functional stress. The therapeutic use supports management of symptoms linked to organ-specific functional stress and helps improve day-to-day comfort during symptomatic periods, especially when used in steroid-sparing strategies.

Quick Fact: Support for Inflammatory Symptoms
Symptom Focus: Helps address symptom clusters that may become intense or disruptive, such as joint pain and swelling in active arthritis and chronic inflammation in the gut.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Azaprin — Official Regulatory Information

This medication is governed by strict eligibility rules established by regulatory authorities.

Eligibility Scope

Classification Population or Condition
Populations for whom use is allowed Adults for approved indications; Pediatric patients for renal allograft rejection prophylaxis.
Populations for whom use is not recommended Breastfeeding women; Concurrent use with other Disease Modifying Anti-Rheumatic Drugs (DMARDs).
Populations for whom use is contraindicated Patients with Hypersensitivity to Azaprin or its metabolite, 6-mercaptopurine; Pregnant women for the Rheumatoid Arthritis indication; Patients with a history of prior treatment with alkylating agents for RA; Patients with Severe Infection.

Eligibility-Related Restrictions

Condition-Specific Rules: Eligibility is restricted by Thiopurine S-methyl transferase (TPMT) and Nucleotide Diphosphatase (NUDT15) enzyme activity. Those with low or absent activity are advised by regulators to consider alternative therapy due to a high risk of life-threatening toxicity. Use requires caution in patients with pre-existing hematologic conditions, hepatic impairment, or renal impairment.

Age and Reproductive Status: Use in older adults requires caution and monitoring due to potentially slower drug clearance. The drug is contraindicated or not recommended during lactation. Use of live vaccines is prohibited during treatment.

What should I know about interactions with other medicines?

The official interaction profile of Azaprin (Azathioprine) is structured around two central concerns: severe toxicity resulting from metabolic interference and the potential for reinforcing drug effects.

Contraindicated and Exposure-Altering Interactions

Co-administration with Live Vaccines is strictly contra-indicated due to the potential for a severe, atypical response resulting from the systemic immune suppression caused by Azaprin.

Major pharmacokinetic interactions occur with agents that block Azaprin's inactivation pathways:

  • Xanthine Oxidase Inhibitors: Medicines such as Allopurinol and Febuxostat inhibit the enzyme responsible for metabolizing the active component. This results in a substantial increase in the active metabolite's plasma concentration, posing a severe risk of myelotoxicity. This combination requires a mandatory adjustment of the Azaprin dose.
  • Ribavirin: This antiviral agent is associated with severe haematological risk, including pancytopenia, due to the accumulation of a specific myelotoxic metabolite (6MTITP).
  • Genetic Factors: Individuals with documented deficiency in the TPMT or NUDT15 hydrolase enzymes have a significantly heightened risk of life-threatening myelosuppression due to metabolite accumulation, a fact noted in prescribing information.

Pharmacodynamic and Other Interactions

Interactions based on reinforcing effects are also documented. Co-administration with other myelosuppressive or cytostatic agents (including some ACE Inhibitors) may enhance the risk of haematological reactions. Furthermore, regulatory documents report that Azaprin may inhibit the anticoagulant effect of certain drugs like Warfarin. Caution is also advised when using Aminosalicylate derivatives (e.g., Sulfasalazine), which may potentially inhibit the TPMT enzyme.

Mechanism of Action

Azaprin functions as a prodrug that is converted into 6-Thioguanine Nucleotides (6-TGNs), which are antimetabolites that interfere with the synthesis of DNA and RNA in proliferating cells . This mechanism prevents immune cells, particularly lymphocytes, from assembling the necessary components for replication, resulting in the inhibition of immune cell proliferation.

The active metabolites also engage in a distinct, non-cytotoxic mechanism by specifically inhibiting the Rac1 small G protein, a key mediator in the T-cell costimulatory signaling cascade . This interference converts the T-cell activation signal into an apoptotic (cell death) signal, leading to the programmed cell death (apoptosis) of actively responsive lymphocytes.

The combination of inhibited proliferation and targeted T-cell apoptosis results in a reduction in the number and activity of circulating lymphocytes. This physiological change leads to a reduction in adaptive immune response activity, which represents the systemic physiological adjustment resulting from the mechanism.

Dosage and Administration Information

Azaprin (Azathioprine) is administered through two officially approved routes: the primary route is oral via tablets, and the secondary route is intravenous (IV) injection, typically reserved for periods when oral intake is not feasible. The IV solution is administered as an infusion over a duration of 30 to 60 minutes and is usually discontinued when the patient can tolerate tablets.

Dosing is standardized according to a weight-based regimen, expressed in milligrams per kilogram of body weight per day (mg/kg/day). For transplant rejection prevention, the initial loading dose is generally between 3 to 5 mg/kg per day, which is then reduced to a maintenance range of 1 to 3 mg/kg per day. For autoimmune indications, the daily dose is not intended to exceed a maximum of 2.5 mg/kg.

The medicine is prescribed for use either once daily or in divided doses. To facilitate proper intake, tablets are generally advised to be taken with or after food but must be taken separately from milk or dairy products. Tablets should be swallowed whole and must not be crushed.

Therapy duration is often long-term (maintained indefinitely) for transplant recipients. For other conditions, a minimum duration of three months is typically required before evaluating the treatment. Dosage adjustments—both increases and reductions—are carried out slowly, generally in step-wise increments over intervals of four to eight weeks. Specific dosing constraints mandate that the Azaprin dose be reduced to one-quarter of the standard amount if co-administered with allopurinol, and lower dosage ranges are applied for older adults and patients with impaired liver or kidney function.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Azaprin (Azathioprina)

This section provides a factual, non-advisory overview of the types of clinical studies that exist for Azaprin, describing the research questions and populations examined, as documented in regulatory and high-quality scientific sources. Findings describe group patterns, not personal outcomes.


Evidence for Use in Kidney Allograft Rejection Prevention

The research into Azaprin’s use in transplant recipients primarily involves Randomized Controlled Trials (RCTs) and Long-term Observational Cohort Studies. These were conducted to explore its role in managing the immune system response that can lead to kidney transplant rejection when used as part of a multi-drug regimen. Researchers monitored outcomes such as the occurrence of acute rejection episodes and measurements of overall graft (organ) survival rates.

Findings described patterns observed in the studies regarding graft survival rates. However, because Azaprin is nearly always used alongside other strong medicines, the specific contribution of Azaprin is often complex to isolate and analyze. This field of evidence also relies on older trials, and its relevance is considered in light of current, evolving transplant protocols.


Evidence for Use in Chronic Inflammatory Conditions

Azaprin was studied for its role in managing several long-term diseases where the immune system is overly active, relevant in trials assessing short-term or episodic symptom patterns.

Rheumatoid Arthritis and Lupus Nephritis

For Rheumatoid Arthritis (RA), the existing evidence base includes RCTs and Meta-analyses. Research examined disease activity measures and outcomes related to physical discomfort. Research highlights changes measured during the study period, with data showing patterns related to a delayed onset of observed changes. The evidence base is generally categorized as moderate, and key limitations include the relatively small sample sizes and the older nature of many trials.

In Lupus Nephritis, research explored its use in maintenance therapy. Researchers monitored outcomes related to the measurement of protein in the urine, the frequency of disease flares, and outcomes related to progression to End-Stage Renal Disease (ESRD). Evidence is often derived from trials comparing Azaprin against alternative agents.


What Is Still Uncertain About Azaprin

While substantial research exists, certainty remains low in several areas. Long-term effects are not fully established for all indications, and evidence is limited for maintenance therapy beyond the first few years in some autoimmune settings. Follow-up durations were limited in many of the older trials. Comparative evidence is lacking for a consistent, head-to-head assessment against all newer therapies now available for chronic conditions. Subgroup findings regarding specific disease variants or patient characteristics are uncertain, meaning results apply only to the populations studied and research is ongoing to fill these data gaps.

Key Studies & References

  1. Azathioprine (NIH/StatPearls)
  2. Azathioprine (NIH MedlinePlus overview)

Frequently Asked Questions (FAQ)

Common questions about Azaprin (FAQ)

Q: How is Azaprin different from other immunosuppressants like cyclosporine or tacrolimus?

Regulatory documents indicate that Azaprin is a distinct medication from other immunosuppressants like cyclosporine. Azaprin is classified as an antimetabolite and a purine analog, meaning it interferes with cell growth, particularly that of immune cells. The regulatory information indicates that Azaprin and other agents like cyclosporine are distinct medications that may be administered concurrently.

Q: What are the signs of a serious problem like liver inflammation or pancreatitis from Azaprin?

Pancreatitis (inflammation of the pancreas) is an uncommon adverse reaction associated with Azaprin. More serious concerns, such as severe bone marrow suppression, may present with symptoms like fever, a sore throat, or unexpected bruising and bleeding. If these signs are observed, official information states that they should be reported immediately to a healthcare provider.

Q: What does the TPMT enzyme test tell us about taking Azaprin?

The TPMT enzyme test identifies individuals who have low or absent activity of this specific enzyme. According to regulatory guidance, these patients are at a significantly increased risk of developing severe, life-threatening toxicity from conventional doses of Azaprin. Pre-treatment testing helps the healthcare provider understand this risk.

Q: Can Azaprin affect the effectiveness of blood thinners like warfarin?

Yes, official prescribing information indicates that Azaprin may reduce or 'inhibit the anticoagulant effect' of certain blood thinners, such as warfarin. If Azaprin is administered with an anticoagulant, monitoring of the blood clotting levels may be necessary.

Q: How can I reduce my risk of sun sensitivity and skin cancer while on Azaprin?

Official warnings state that long-term immunosuppression can increase the risk of skin cancer. To help manage this risk, official labeling suggests practices such as using sunscreen, wearing protective clothing, and avoiding excessive exposure to sunlight, sunlamps, and tanning beds.

Q: How often are the serious side effects of Azaprin reported in clinical studies?

Regulatory information reports the frequency of various adverse effects by category, such as 'very common' (affecting 10% or more of patients) or 'common' (affecting 1% to 10% of patients). For example, anorexia is listed as a very common effect, while hair loss (alopecia) is common. Serious effects like hypersensitivity reactions are classified as uncommon or rare.

Q: Is it better to take Azaprin with food, and does it matter what kind of food?

Official guidance advises taking Azaprin tablets either with food or immediately after a meal. However, the product information indicates that the tablets should be taken separately from milk or dairy products, as these substances may reduce the oral absorption of the medicine.

Q: Does Azaprin cause or worsen pre-existing digestive problems like diarrhea or stomach ulcers?

Diarrhea is a known side effect and, in some populations, can become severe. The drug can also cause pancreatitis, which is inflammation of the pancreas. If a patient has pre-existing digestive issues, regulatory documents advise caution and monitoring during treatment.

Q: Is Azaprin considered a chemotherapy drug since it affects cell growth?

Azaprin is officially classified as an immunosuppressant and an antimetabolite, a type of medicine that interferes with cell proliferation (growth). It acts as a purine analog, interfering with the synthesis of DNA and RNA, primarily in rapidly dividing immune cells. The term 'chemotherapy' is not the official classification for this drug's general use.

Q: What conditions, besides rheumatoid arthritis and organ transplants, is Azaprin used for?

According to the official product labeling, the two primary FDA-approved indications are for the prophylaxis (prevention) of kidney transplant rejection and for the treatment of severe, active rheumatoid arthritis.

Q: Does Azaprin suppress the entire immune system or only certain parts?

Azaprin works by selectively targeting and reducing the number and activity of circulating lymphocytes, particularly T-cells and B-cells, which are key components of the adaptive immune system. This targeted action results in a broad reduction in adaptive immune response activity.

Q: What is the longest period of time people typically stay on Azaprin therapy?

Official dosing guidelines state that for patients who have received an organ transplant, therapy with Azaprin is often maintained indefinitely to prevent rejection. For other conditions, the duration is typically determined by the response to treatment, with a minimum of three months usually required before the treatment is evaluated.

Q: How quickly should I expect to see an improvement in my symptoms after starting Azaprin?

Studies and official information indicate that the clinical response from Azaprin is not immediate. It may take several weeks or even a few months for improvements to become noticeable. Treatment is typically required for a minimum of three months before a full evaluation of its effectiveness can be made.

Q: Why does Azaprin sometimes cause flu-like symptoms after starting the medication?

Flu-like symptoms, which may include muscle pain, headache, and diarrhea, are listed in official documents as a common adverse reaction. These symptoms are most likely to occur in the first two to three weeks after a patient begins treatment with Azaprin.

Q: Is hair loss a common or permanent side effect of Azaprin?

Alopecia, or hair loss, is listed in the regulatory documents as a common side effect of Azaprin therapy. The official product information does not explicitly state whether this hair loss is temporary or permanent.

Q: Are there any common herbal supplements or vitamins known to interact with Azaprin?

While specific herbal products are not typically listed in official interaction tables, patients are advised to inform their healthcare provider about all vitamins, minerals, herbal products, and other supplements they are taking. This is necessary because some may interfere with Azaprin or its effects.

Q: What should I do if I accidentally get pregnant while taking Azaprin?

Due to the potential for harm to the fetus, official regulatory documents state that if pregnancy occurs, the patient should be apprised of the potential harm and immediately contact their healthcare provider.

Q: Can Azaprin cause weight gain or weight loss?

Official safety information lists anorexia, a loss of appetite, as a very common side effect, which may be associated with weight loss. Weight gain is not listed as a common or very common side effect.

Q: Are there any diet restrictions to follow while on Azaprin therapy?

The primary dietary restriction noted in official guidance relates only to the administration of the dose. Tablets should be taken with or after food, but specifically should be taken separately from milk or any other dairy products.

Q: Does Azaprin affect my energy levels or cause chronic fatigue?

Fatigue is listed in the regulatory documentation as a possible side effect. Furthermore, the drug’s potential to cause myelosuppression (bone marrow problems) may lead to symptoms of unusual tiredness or weakness.

Q: Is it true that Azaprin may make me more susceptible to viral illnesses like shingles?

Yes, official safety information states that because Azaprin is an immunosuppressant, it increases the risk of viral infections. This includes the possibility of more severe infection from common viruses such as chickenpox or shingles.

Q: How does Azaprin affect fertility in men and women?

Animal studies cited in the regulatory documents have shown that Azaprin can cause a temporary decrease in sperm production in male mice. However, adequately controlled human studies specifically looking at the effect on fertility in men and women have not been conducted.

Q: What are the signs of a hypersensitivity or allergic reaction to Azaprin?

Hypersensitivity or allergic reactions, which are uncommon, may present with symptoms such as fever, chills, nausea, vomiting, headache, rash, muscle pain, or weakness. Patients are advised to look out for any of these signs of an unusual reaction.

Q: Is it possible to take Azaprin once a day instead of splitting the dose?

Yes, Azaprin can be prescribed by a healthcare provider for use either as a once-daily dose or as a dose split into multiple administrations per day.

Q: What should I watch out for that indicates I need an immediate doctor's visit while on Azaprin?

Official warnings state that signs such as fever, a sore throat, unexpected bruising, or bleeding should be reported to a healthcare provider immediately.

Q: Does Azaprin affect mental health or mood?

In very rare instances, a serious brain condition called Progressive Multifocal Leukoencephalopathy (PML) has been reported in patients taking Azaprin. This condition may involve changes in behavior and mood, such as confusion, memory problems, or depression.

Q: What specific monitoring is done to prevent bone marrow problems from Azaprin?

To monitor for bone marrow problems, complete blood counts (CBCs), including platelet counts, are performed frequently. This monitoring typically starts weekly or more often during the first eight weeks of therapy and then continues monthly or at least every three months thereafter.

How should Azaprin be stored and disposed of?

Official Storage and Disposal Instructions

Azaprin (azathioprine) must be stored at controlled room temperature, specifically between 15 C to 25 C (59 F to 77 F). The product must be protected from light and moisture and should not be frozen or exposed to excess heat.


Container and Safety Rules

The tablets should remain in the original container with the cap tightly closed. A mandatory storage instruction is to keep the medicine out of the sight and reach of children at all times.


Handling and Disposal

As this medication is classified as a cytotoxic and hazardous drug, specific handling precautions are required. Unused or expired Azaprin must not be kept; it requires disposal strictly according to local regulations. Patients should consult a pharmacist or healthcare provider for the proper method of disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azaprin found in:

A-Z Index: